Neurocrine Biosciences Inc (NBIX)vsUnited Therapeutics Corporation (UTHR)
NBIX
Neurocrine Biosciences Inc
$127.68
-1.56%
HEALTHCARE · Cap: $13.12B
UTHR
United Therapeutics Corporation
$524.28
-0.52%
HEALTHCARE · Cap: $23.67B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 11% more annual revenue ($3.18B vs $2.86B). UTHR leads profitability with a 41.9% profit margin vs 16.7%. NBIX appears more attractively valued with a PEG of 0.27. NBIX earns a higher WallStSmart Score of 75/100 (B+).
NBIX
Strong Buy75
out of 100
Grade: B+
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+37.1%
Fair Value
$218.56
Current Price
$127.68
$90.88 discount
Margin of Safety
+63.2%
Fair Value
$1294.44
Current Price
$524.28
$770.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 28.2%
Revenue surging 28.3% year-over-year
Earnings expanding 47.7% YoY
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.7% and operating margin at 28.2%. Revenue growth of 28.3% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : NBIX
The primary concerns for NBIX are P/E Ratio, Piotroski F-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
NBIX profiles as a growth stock while UTHR is a mature play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.86 — expect wider price swings.
NBIX is growing revenue faster at 28.3% — sustainability is the question.
NBIX generates stronger free cash flow (386M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (75/100 vs 67/100), backed by strong 16.7% margins and 28.3% revenue growth. UTHR offers better value entry with a 63.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?